Fate Therapeutics Inc. (NASDAQ:FATE) fell 2.9% during trading on Tuesday . The company traded as low as $2.58 and last traded at $2.65, with a volume of 106,626 shares changing hands. The stock had previously closed at $2.73.

Several equities research analysts have recently issued reports on the company. Zacks Investment Research cut Fate Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, May 4th. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Fate Therapeutics in a report on Tuesday, May 10th. BMO Capital Markets reaffirmed a “buy” rating on shares of Fate Therapeutics in a report on Tuesday, May 10th. Leerink Swann reaffirmed an “outperform” rating and issued a $4.00 target price on shares of Fate Therapeutics in a report on Tuesday, June 21st. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Fate Therapeutics in a report on Tuesday, August 9th. Eight equities research analysts have rated the stock with a buy rating, Fate Therapeutics has an average rating of “Buy” and a consensus price target of $6.29.

The company has a 50-day moving average of $1.99 and a 200-day moving average of $1.85. The company’s market capitalization is $82.06 million.

Fate Therapeutics (NASDAQ:FATE) last posted its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.03. The business earned $1.03 million during the quarter, compared to analysts’ expectations of $1.02 million. Equities research analysts expect that Fate Therapeutics Inc. will post ($1.12) EPS for the current year.

Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.